New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)